Get the Stockscreener App
5.63
2.60%
-0.15
4 D Molecular Therapeutics Inc stock is traded at $5.63, with a volume of 551.69K.
It is down -2.60% in the last 24 hours and up +33.41% over the past month.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
See More
Previous Close:
$5.78
Open:
$5.83
24h Volume:
551.69K
Relative Volume:
0.56
Market Cap:
$260.81M
Revenue:
$20.72M
Net Income/Loss:
$-100.84M
P/E Ratio:
-2.1165
EPS:
-2.66
Net Cash Flow:
$-78.56M
1W Performance:
-12.31%
1M Performance:
+33.41%
6M Performance:
-5.70%
1Y Performance:
-61.78%
1-Day Range:
$5.50
$5.9414
1-Week Range:
$5.11
$6.1787
52-Week Range:
$2.235
$17.41
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Name
4 D Molecular Therapeutics Inc
Sector
Industry
Phone
(510) 505-2680
Address
5858 HORTON STREET #455, EMERYVILLE
Compare FDMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
5.63 | 265.44M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Nov-21-24 | Initiated | Morgan Stanley | Underweight |
| Sep-23-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Apr-15-24 | Initiated | Barclays | Overweight |
| Feb-07-24 | Resumed | Goldman | Buy |
| Oct-26-23 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-18-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-23 | Initiated | BMO Capital Markets | Outperform |
| Nov-18-22 | Initiated | H.C. Wainwright | Buy |
| Nov-15-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-12-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-22-22 | Initiated | Jefferies | Buy |
| Jan-04-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-21 | Initiated | BofA Securities | Buy |
| Jan-05-21 | Initiated | Evercore ISI | Outperform |
| Jan-05-21 | Initiated | Goldman | Neutral |
View All
4 D Molecular Therapeutics Inc Stock (FDMT) Latest News
Technical analysis overview for 4D Molecular Therapeutics Inc. stockFree Portfolio Diversification Stock Ideas - Newser
Using AI based signals to follow 4D Molecular Therapeutics Inc.Long-Term Safety Investment Analysis Report - Newser
Heatmap analysis for 4D Molecular Therapeutics Inc. and competitorsFree Momentum Based Equity Trading Plan - Newser
Is 4D Molecular Therapeutics Inc. forming a reversal patternAI-Based Reversal Point Prediction Signal - Newser
Why 4D Molecular Therapeutics Inc. stock attracts strong analyst attentionBuy Candidate Summary Based on Fundamentals - Newser
Can you recover from losses in 4D Molecular Therapeutics Inc.Daily Profit Watch With Forecast Confidence - Newser
Developing predictive dashboards with 4D Molecular Therapeutics Inc. dataFree Market Momentum and Signal Alerts - Newser
Can trapped investors hope for a rebound in 4D Molecular Therapeutics Inc.AI Enhanced Strategy for Portfolio Growth - Newser
Will 4D Molecular Therapeutics Inc. price bounce be sustainableReal-Time Entry Signals for Top Stocks - Newser
Will earnings trigger a reversal in 4D Molecular Therapeutics Inc.Volume Spike Detection for Early Breakouts - Newser
What technical models suggest about 4D Molecular Therapeutics Inc.’s comebackAI Powered Stock Trend Prediction Model - Newser
What makes 4D Molecular Therapeutics Inc. stock attractive to long term investorsFree Real Market Momentum Signal Generator - Newser
4D Molecular Therapeutics to Participate in H.C. Wainwright Ophthalmology Virtual Conference - AInvest
4D Molecular Therapeutics shares fall 1.92% premarket ahead of H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. - AInvest
Published on: 2025-08-07 03:01:11 - Newser
4D Molecular Therapeutics (FDMT) to Release Earnings on Thursday - Defense World
4D Molecular Therapeutics shares fall 2.73% intraday after announcing participation in H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. - AInvest
Volatility clustering patterns for 4D Molecular Therapeutics Inc.Short-Term Sector Movement Forecast Generator - Newser
Using fundamentals and technicals on 4D Molecular Therapeutics Inc.AI Volatility Forecast and Risk Monitor - Newser
4D Molecular Therapeutics Inc expected to post a loss of 88 cents a shareEarnings Preview - TradingView
How to build a custom watchlist for 4D Molecular Therapeutics Inc.Entry Opportunity Screener with Confirmation - Newser
Fibonacci Support Holding Strong in 4D Molecular Therapeutics Inc.Conservative Long Term Growth Plans Under Review - beatles.ru
Why is 4D Molecular Therapeutics Inc. stock attracting strong analyst attentionAchieve consistent profits with proven methods - Jammu Links News
4D Molecular Therapeutics’ (FDMT) Buy Rating Reiterated at Chardan Capital - Defense World
Is 4D Molecular Therapeutics Inc. a growth stock or a value stockProven strategies for superior portfolio growth - Jammu Links News
What is the dividend policy of 4D Molecular Therapeutics Inc. stockGet daily expert analysis on top stocks - Jammu Links News
Is 4D Molecular Therapeutics Inc. Stock a Good Fit for Conservative InvestorsFree Capital Preserving Trade Plan Templates - Newser
What is the risk reward ratio of investing in 4D Molecular Therapeutics Inc. stockExplosive capital gains - Jammu Links News
What are 4D Molecular Therapeutics Inc. company’s key revenue driversCapitalize on fast-growing investment opportunities - Jammu Links News
Does 4D Molecular Therapeutics Inc. stock perform well during market downturnsRapid profit acceleration - Jammu Links News
Is 4D Molecular Therapeutics Inc. stock overvalued or undervaluedInvest smarter with data-backed trading alerts - Jammu Links News
What are the technical indicators suggesting about 4D Molecular Therapeutics Inc.Spectacular growth rates - Jammu Links News
When is 4D Molecular Therapeutics Inc. stock expected to show significant growthMassive stock growth - Jammu Links News
4D Molecular Therapeutics Inc. stock prediction for this weekLow Drawdown Picks with Weekly Updates - Newser
4D Molecular Therapeutics Showcases Positive Trial Results, Charts New Growth Trajectory - timothysykes.com
4D Molecular (FDMT) Stock Climbs Following Promising Retina Therapy Data - Stocks Telegraph
4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study - 富途牛牛
How volatile is 4D Molecular Therapeutics Inc. stock compared to the marketEntry Signal Forecasts With Low Risk - Jammu Links News
4D Molecular: Time to Buy After Recent Surge? - StocksToTrade
4D Molecular Therapeutics: A Market Shift? - timothysykes.com
4D Molecular Therapeutics shares rise 30.44% premarket after presenting positive 60-week results for 4D-150. - AInvest
Chardan Capital Maintains Buy on 4D Molecular, Raises PT to $25 - AInvest
4D Molecular Therapeutics stock soars after positive DME trial results By Investing.com - Investing.com Canada
Will a bounce in 4D Molecular Therapeutics Inc. offer an exitPrice Action Trading with Volume Confirmation - Newser
4D Molecular Therapeutics Shares Surge 50.89% on Positive Clinical Trial Results - AInvest
4D Molecular Therapeutics (FDMT) Shares Soar 37.78% on Positive Clinical Trial Results - AInvest
4D Molecular Therapeutics shares rise 56% premarket after presenting positive 60-week results for 4D-150. - AInvest
4D Molecular (FDMT) Shows Promising Results in Clinical Trial fo - GuruFocus
4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update - GlobeNewswire
Breakthrough: 4D-150 DME Treatment Shows 78% Reduction in Injections, FDA and EMA Clear Path to Approval - Stock Titan
How does 4D Molecular Therapeutics Inc. compare to its industry peersBeginner Investor Strategy With Proven Results - Jammu Links News
4 D Molecular Therapeutics Inc Stock (FDMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
3.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):